 | • レポートコード：MRC2-11QY12079 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は婦人科がんのグローバル市場について調査・分析したレポートです。種類別（化学療法、標的療法、ホルモン療法）市場規模、用途別（病院、クリニック、専門がん治療センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別婦人科がんの競争状況、市場シェア ・世界の婦人科がん市場：種類別市場規模 2015年-2020年（化学療法、標的療法、ホルモン療法） ・世界の婦人科がん市場：種類別市場規模予測 2021年-2026年（化学療法、標的療法、ホルモン療法） ・世界の婦人科がん市場：用途別市場規模 2015年-2020年（病院、クリニック、専門がん治療センター） ・世界の婦人科がん市場：用途別市場規模予測 2021年-2026年（病院、クリニック、専門がん治療センター） ・北米の婦人科がん市場分析：米国、カナダ ・ヨーロッパの婦人科がん市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの婦人科がん市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の婦人科がん市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの婦人科がん市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：GlaxoSmithKline、Becton Dickinson、Eli Lilly、Bristol Myers Squibb、F. Hoffmann、Apotex、AstraZeneca、Novartis、Merck、Pfizer、Teva Pharmaceutical ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Gynecological cancers are characterized by uncontrolled growth and spread of abnormal cells.
The growth of the global gynecological cancer drugs market is driven by factors such as increase in incidence of gynecological cancers, growth in importance of targeted drug therapies, rise in investment from government, public & private organizations for the development of novel drugs to treat cancer, and increase in risk factors that lead to cancer.
Market Analysis and Insights: Global Gynecological Cancers Market
The global Gynecological Cancers market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Gynecological Cancers Scope and Market Size
Gynecological Cancers market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Gynecological Cancers market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
GlaxoSmithKline
Becton Dickinson
Eli Lilly
Bristol Myers Squibb
F. Hoffmann
Apotex
AstraZeneca
Novartis
Merck
Pfizer
Teva Pharmaceutical
Market segment by Type, the product can be split into
Chemotherapy
Targeted Therapy
Hormonal Therapy
Market segment by Application, split into
Hospitals
Clinics
Specialized Cancer Treatment Centers
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Gynecological Cancers Revenue
1.4 Market by Type
1.4.1 Global Gynecological Cancers Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Chemotherapy
1.4.3 Targeted Therapy
1.4.4 Hormonal Therapy
1.5 Market by Application
1.5.1 Global Gynecological Cancers Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Specialized Cancer Treatment Centers
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Gynecological Cancers Market Perspective (2015-2026)
2.2 Global Gynecological Cancers Growth Trends by Regions
2.2.1 Gynecological Cancers Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Gynecological Cancers Historic Market Share by Regions (2015-2020)
2.2.3 Gynecological Cancers Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Gynecological Cancers Market Growth Strategy
2.3.6 Primary Interviews with Key Gynecological Cancers Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Gynecological Cancers Players by Market Size
3.1.1 Global Top Gynecological Cancers Players by Revenue (2015-2020)
3.1.2 Global Gynecological Cancers Revenue Market Share by Players (2015-2020)
3.1.3 Global Gynecological Cancers Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Gynecological Cancers Market Concentration Ratio
3.2.1 Global Gynecological Cancers Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Gynecological Cancers Revenue in 2019
3.3 Gynecological Cancers Key Players Head office and Area Served
3.4 Key Players Gynecological Cancers Product Solution and Service
3.5 Date of Enter into Gynecological Cancers Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Gynecological Cancers Historic Market Size by Type (2015-2020)
4.2 Global Gynecological Cancers Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Gynecological Cancers Market Size by Application (2015-2020)
5.2 Global Gynecological Cancers Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Gynecological Cancers Market Size (2015-2020)
6.2 Gynecological Cancers Key Players in North America (2019-2020)
6.3 North America Gynecological Cancers Market Size by Type (2015-2020)
6.4 North America Gynecological Cancers Market Size by Application (2015-2020)
7 Europe
7.1 Europe Gynecological Cancers Market Size (2015-2020)
7.2 Gynecological Cancers Key Players in Europe (2019-2020)
7.3 Europe Gynecological Cancers Market Size by Type (2015-2020)
7.4 Europe Gynecological Cancers Market Size by Application (2015-2020)
8 China
8.1 China Gynecological Cancers Market Size (2015-2020)
8.2 Gynecological Cancers Key Players in China (2019-2020)
8.3 China Gynecological Cancers Market Size by Type (2015-2020)
8.4 China Gynecological Cancers Market Size by Application (2015-2020)
9 Japan
9.1 Japan Gynecological Cancers Market Size (2015-2020)
9.2 Gynecological Cancers Key Players in Japan (2019-2020)
9.3 Japan Gynecological Cancers Market Size by Type (2015-2020)
9.4 Japan Gynecological Cancers Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Gynecological Cancers Market Size (2015-2020)
10.2 Gynecological Cancers Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Gynecological Cancers Market Size by Type (2015-2020)
10.4 Southeast Asia Gynecological Cancers Market Size by Application (2015-2020)
11 India
11.1 India Gynecological Cancers Market Size (2015-2020)
11.2 Gynecological Cancers Key Players in India (2019-2020)
11.3 India Gynecological Cancers Market Size by Type (2015-2020)
11.4 India Gynecological Cancers Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Gynecological Cancers Market Size (2015-2020)
12.2 Gynecological Cancers Key Players in Central & South America (2019-2020)
12.3 Central & South America Gynecological Cancers Market Size by Type (2015-2020)
12.4 Central & South America Gynecological Cancers Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 GlaxoSmithKline
13.1.1 GlaxoSmithKline Company Details
13.1.2 GlaxoSmithKline Business Overview
13.1.3 GlaxoSmithKline Gynecological Cancers Introduction
13.1.4 GlaxoSmithKline Revenue in Gynecological Cancers Business (2015-2020))
13.1.5 GlaxoSmithKline Recent Development
13.2 Becton Dickinson
13.2.1 Becton Dickinson Company Details
13.2.2 Becton Dickinson Business Overview
13.2.3 Becton Dickinson Gynecological Cancers Introduction
13.2.4 Becton Dickinson Revenue in Gynecological Cancers Business (2015-2020)
13.2.5 Becton Dickinson Recent Development
13.3 Eli Lilly
13.3.1 Eli Lilly Company Details
13.3.2 Eli Lilly Business Overview
13.3.3 Eli Lilly Gynecological Cancers Introduction
13.3.4 Eli Lilly Revenue in Gynecological Cancers Business (2015-2020)
13.3.5 Eli Lilly Recent Development
13.4 Bristol Myers Squibb
13.4.1 Bristol Myers Squibb Company Details
13.4.2 Bristol Myers Squibb Business Overview
13.4.3 Bristol Myers Squibb Gynecological Cancers Introduction
13.4.4 Bristol Myers Squibb Revenue in Gynecological Cancers Business (2015-2020)
13.4.5 Bristol Myers Squibb Recent Development
13.5 F. Hoffmann
13.5.1 F. Hoffmann Company Details
13.5.2 F. Hoffmann Business Overview
13.5.3 F. Hoffmann Gynecological Cancers Introduction
13.5.4 F. Hoffmann Revenue in Gynecological Cancers Business (2015-2020)
13.5.5 F. Hoffmann Recent Development
13.6 Apotex
13.6.1 Apotex Company Details
13.6.2 Apotex Business Overview
13.6.3 Apotex Gynecological Cancers Introduction
13.6.4 Apotex Revenue in Gynecological Cancers Business (2015-2020)
13.6.5 Apotex Recent Development
13.7 AstraZeneca
13.7.1 AstraZeneca Company Details
13.7.2 AstraZeneca Business Overview
13.7.3 AstraZeneca Gynecological Cancers Introduction
13.7.4 AstraZeneca Revenue in Gynecological Cancers Business (2015-2020)
13.7.5 AstraZeneca Recent Development
13.8 Novartis
13.8.1 Novartis Company Details
13.8.2 Novartis Business Overview
13.8.3 Novartis Gynecological Cancers Introduction
13.8.4 Novartis Revenue in Gynecological Cancers Business (2015-2020)
13.8.5 Novartis Recent Development
13.9 Merck
13.9.1 Merck Company Details
13.9.2 Merck Business Overview
13.9.3 Merck Gynecological Cancers Introduction
13.9.4 Merck Revenue in Gynecological Cancers Business (2015-2020)
13.9.5 Merck Recent Development
13.10 Pfizer
13.10.1 Pfizer Company Details
13.10.2 Pfizer Business Overview
13.10.3 Pfizer Gynecological Cancers Introduction
13.10.4 Pfizer Revenue in Gynecological Cancers Business (2015-2020)
13.10.5 Pfizer Recent Development
13.11 Teva Pharmaceutical
10.11.1 Teva Pharmaceutical Company Details
10.11.2 Teva Pharmaceutical Business Overview
10.11.3 Teva Pharmaceutical Gynecological Cancers Introduction
10.11.4 Teva Pharmaceutical Revenue in Gynecological Cancers Business (2015-2020)
10.11.5 Teva Pharmaceutical Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Gynecological Cancers Key Market Segments
Table 2. Key Players Covered: Ranking by Gynecological Cancers Revenue
Table 3. Ranking of Global Top Gynecological Cancers Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Gynecological Cancers Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Chemotherapy
Table 6. Key Players of Targeted Therapy
Table 7. Key Players of Hormonal Therapy
Table 8. Global Gynecological Cancers Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Gynecological Cancers Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Gynecological Cancers Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Gynecological Cancers Market Share by Regions (2015-2020)
Table 12. Global Gynecological Cancers Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Gynecological Cancers Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Gynecological Cancers Market Growth Strategy
Table 18. Main Points Interviewed from Key Gynecological Cancers Players
Table 19. Global Gynecological Cancers Revenue by Players (2015-2020) (Million US$)
Table 20. Global Gynecological Cancers Market Share by Players (2015-2020)
Table 21. Global Top Gynecological Cancers Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gynecological Cancers as of 2019)
Table 22. Global Gynecological Cancers by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Gynecological Cancers Product Solution and Service
Table 25. Date of Enter into Gynecological Cancers Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Gynecological Cancers Market Size by Type (2015-2020) (Million US$)
Table 28. Global Gynecological Cancers Market Size Share by Type (2015-2020)
Table 29. Global Gynecological Cancers Revenue Market Share by Type (2021-2026)
Table 30. Global Gynecological Cancers Market Size Share by Application (2015-2020)
Table 31. Global Gynecological Cancers Market Size by Application (2015-2020) (Million US$)
Table 32. Global Gynecological Cancers Market Size Share by Application (2021-2026)
Table 33. North America Key Players Gynecological Cancers Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Gynecological Cancers Market Share (2019-2020)
Table 35. North America Gynecological Cancers Market Size by Type (2015-2020) (Million US$)
Table 36. North America Gynecological Cancers Market Share by Type (2015-2020)
Table 37. North America Gynecological Cancers Market Size by Application (2015-2020) (Million US$)
Table 38. North America Gynecological Cancers Market Share by Application (2015-2020)
Table 39. Europe Key Players Gynecological Cancers Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Gynecological Cancers Market Share (2019-2020)
Table 41. Europe Gynecological Cancers Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Gynecological Cancers Market Share by Type (2015-2020)
Table 43. Europe Gynecological Cancers Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Gynecological Cancers Market Share by Application (2015-2020)
Table 45. China Key Players Gynecological Cancers Revenue (2019-2020) (Million US$)
Table 46. China Key Players Gynecological Cancers Market Share (2019-2020)
Table 47. China Gynecological Cancers Market Size by Type (2015-2020) (Million US$)
Table 48. China Gynecological Cancers Market Share by Type (2015-2020)
Table 49. China Gynecological Cancers Market Size by Application (2015-2020) (Million US$)
Table 50. China Gynecological Cancers Market Share by Application (2015-2020)
Table 51. Japan Key Players Gynecological Cancers Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Gynecological Cancers Market Share (2019-2020)
Table 53. Japan Gynecological Cancers Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Gynecological Cancers Market Share by Type (2015-2020)
Table 55. Japan Gynecological Cancers Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Gynecological Cancers Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Gynecological Cancers Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Gynecological Cancers Market Share (2019-2020)
Table 59. Southeast Asia Gynecological Cancers Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Gynecological Cancers Market Share by Type (2015-2020)
Table 61. Southeast Asia Gynecological Cancers Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Gynecological Cancers Market Share by Application (2015-2020)
Table 63. India Key Players Gynecological Cancers Revenue (2019-2020) (Million US$)
Table 64. India Key Players Gynecological Cancers Market Share (2019-2020)
Table 65. India Gynecological Cancers Market Size by Type (2015-2020) (Million US$)
Table 66. India Gynecological Cancers Market Share by Type (2015-2020)
Table 67. India Gynecological Cancers Market Size by Application (2015-2020) (Million US$)
Table 68. India Gynecological Cancers Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Gynecological Cancers Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Gynecological Cancers Market Share (2019-2020)
Table 71. Central & South America Gynecological Cancers Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Gynecological Cancers Market Share by Type (2015-2020)
Table 73. Central & South America Gynecological Cancers Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Gynecological Cancers Market Share by Application (2015-2020)
Table 75. GlaxoSmithKline Company Details
Table 76. GlaxoSmithKline Business Overview
Table 77. GlaxoSmithKline Product
Table 78. GlaxoSmithKline Revenue in Gynecological Cancers Business (2015-2020) (Million US$)
Table 79. GlaxoSmithKline Recent Development
Table 80. Becton Dickinson Company Details
Table 81. Becton Dickinson Business Overview
Table 82. Becton Dickinson Product
Table 83. Becton Dickinson Revenue in Gynecological Cancers Business (2015-2020) (Million US$)
Table 84. Becton Dickinson Recent Development
Table 85. Eli Lilly Company Details
Table 86. Eli Lilly Business Overview
Table 87. Eli Lilly Product
Table 88. Eli Lilly Revenue in Gynecological Cancers Business (2015-2020) (Million US$)
Table 89. Eli Lilly Recent Development
Table 90. Bristol Myers Squibb Company Details
Table 91. Bristol Myers Squibb Business Overview
Table 92. Bristol Myers Squibb Product
Table 93. Bristol Myers Squibb Revenue in Gynecological Cancers Business (2015-2020) (Million US$)
Table 94. Bristol Myers Squibb Recent Development
Table 95. F. Hoffmann Company Details
Table 96. F. Hoffmann Business Overview
Table 97. F. Hoffmann Product
Table 98. F. Hoffmann Revenue in Gynecological Cancers Business (2015-2020) (Million US$)
Table 99. F. Hoffmann Recent Development
Table 100. Apotex Company Details
Table 101. Apotex Business Overview
Table 102. Apotex Product
Table 103. Apotex Revenue in Gynecological Cancers Business (2015-2020) (Million US$)
Table 104. Apotex Recent Development
Table 105. AstraZeneca Company Details
Table 106. AstraZeneca Business Overview
Table 107. AstraZeneca Product
Table 108. AstraZeneca Revenue in Gynecological Cancers Business (2015-2020) (Million US$)
Table 109. AstraZeneca Recent Development
Table 110. Novartis Business Overview
Table 111. Novartis Product
Table 112. Novartis Company Details
Table 113. Novartis Revenue in Gynecological Cancers Business (2015-2020) (Million US$)
Table 114. Novartis Recent Development
Table 115. Merck Company Details
Table 116. Merck Business Overview
Table 117. Merck Product
Table 118. Merck Revenue in Gynecological Cancers Business (2015-2020) (Million US$)
Table 119. Merck Recent Development
Table 120. Pfizer Company Details
Table 121. Pfizer Business Overview
Table 122. Pfizer Product
Table 123. Pfizer Revenue in Gynecological Cancers Business (2015-2020) (Million US$)
Table 124. Pfizer Recent Development
Table 125. Teva Pharmaceutical Company Details
Table 126. Teva Pharmaceutical Business Overview
Table 127. Teva Pharmaceutical Product
Table 128. Teva Pharmaceutical Revenue in Gynecological Cancers Business (2015-2020) (Million US$)
Table 129. Teva Pharmaceutical Recent Development
Table 130. Research Programs/Design for This Report
Table 131. Key Data Information from Secondary Sources
Table 132. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Gynecological Cancers Market Share by Type: 2020 VS 2026
Figure 2. Chemotherapy Features
Figure 3. Targeted Therapy Features
Figure 4. Hormonal Therapy Features
Figure 5. Global Gynecological Cancers Market Share by Application: 2020 VS 2026
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Specialized Cancer Treatment Centers Case Studies
Figure 9. Gynecological Cancers Report Years Considered
Figure 10. Global Gynecological Cancers Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Gynecological Cancers Market Share by Regions: 2020 VS 2026
Figure 12. Global Gynecological Cancers Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Gynecological Cancers Market Share by Players in 2019
Figure 15. Global Top Gynecological Cancers Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gynecological Cancers as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Gynecological Cancers Revenue in 2019
Figure 17. North America Gynecological Cancers Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Gynecological Cancers Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Gynecological Cancers Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Gynecological Cancers Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Gynecological Cancers Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Gynecological Cancers Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Gynecological Cancers Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed
非血液がんの世界市場（～2026年） Non-Hematological cancers which cover lung cancer, prostate cancer, breast cancer and others, this type of cancer are not show easily diagnosis and the treatment process is also show long that some time it lead to the death of the patient. North America has the huge number of population suffering fr…- 膵臓がん治療の世界市場（～2026年） Pancreatic cancer therapy is recommended by clinicians for early detection of cancer. Pancreatic cancer generally diagnosed at a later stage, since the symptoms are not easily detected or diagnosed. Factors such as, chronic inflammation of the pancreas (pancreatitis), diabetes, smoking, and obesity …
- 粒子線治療の世界市場（～2026年） Particle therapy is a form of external beam radiotherapy using beams of energetic protons, neutrons, or positive ions for cancer treatment. The most common type of particle therapy is proton therapy. Market Analysis and Insights: Global Particle Therapy Market The global Particle Therapy market size…
- 転移性がん治療の世界市場（～2026年） Metastatic breast cancer is an advanced stage of breast cancer. It involves cases in which breast cancer has spread to the other parts of the body. Some of the most common organs which are affected by metastatic breast cancer are brain, liver, bones and lungs. It is also known as stage IV breast can…
- 卵巣がん遺伝子治療の世界市場（～2026年） Ovarian cancer occurs and arises from several types of cells within the ovary, and it has the lowest survival rate of all gynecological cancers. Among many types, epithelial ovarian cancer (EOC) is the most common ovarian cancer, whereas ovarian low malignant potential tumor (OLMPT), germ cell tumor…